<DOC>
	<DOCNO>NCT00823719</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ofatumumab use combination ifosfamide , carboplatin , etoposide ( ICE ) dexamethasone , cytarabine , cisplatin ( DHAP ) salvage chemotherapy regimens subject relapse refractory diffuse large B cell lymphoma ( DLBCL ) eligible autologous stem cell transplant .</brief_summary>
	<brief_title>Phase II Study Ofatumumab Plus Ifosfamide , Carboplatin , Etoposide ( ICE ) Dexamethasone , Cytarabine , Cisplatin ( DHAP ) Chemotherapy Regimen Relapsed/ Refractory Diffuse Large B Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>Rituximab combine anthracycline base chemotherapy common first-line treatment subject diffuse large B cell lymphoma ( DLBCL ) . Subjects require second-line therapy often receive rituximab combination salvage chemotherapy induction therapy prior autologous stem cell transplant . With rituximab first-line therapy , response rate subject receive rituximab plus salvage chemotherapy significantly decrease . Treatment ofatumumab may able overcome resistance rituximab second-line setting offer improved response rate . The objective study evaluate overall response rate ofatumumab combination ICE DHAP chemotherapy prior autologous stem cell transplant . Additional objective evaluate complete response rate , ability mobilize cluster differentiation ( CD ) 34+ cell , progression-free survival ( PFS ) overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects CD20 positive aggressive nonHodgkin 's lymphoma ( NHL ) include DLBCL , transform follicular lymphoma ( FL ) &amp; grade 3b FL . Refractory , relapse following , firstline treatment rituximab combine anthracycline anthracenedionebased chemotherapy define protocol . Computed tomography ( CT ) involvement 2 clearly demarcated lesion long axis &gt; 1.5 centimeter ( cm ) short axis ≥ 1.0 cm 1 clearly demarcated lesion long axis &gt; 2.0 cm short axis ≥1.0 cm . Baseline [ 18F ] fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) scan must demonstrate positive lesion compatible CT define anatomical tumor site . Age 18 yr old . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Eligible high dose chemotherapy autologous stem cell transplant ( ASCT ) . Resolution toxicity firstline therapy grade opinion investigator contraindicate study participation . Signed write informed consent . Previous cancer therapy lymphoma , exception require rituximab/ anthracycline anthracenedionebased chemotherapy , monotherapy rituximab prior firstline therapy / maintenance therapy , limited field radiotherapy ( define protocol ) . Any anticancer therapy , except limited field radiotherapy , within 2 week prior start study therapy . Chronic Glucocorticoid use ( limited acute use allow define protocol ) . History significant cerebrovascular disease . Abnormal/ inadequate white blood cell ( WBC ) count , liver , kidney function . Clinically significant cardiac disease , active chronic infection , serious significant disease , cancer within last 5 year . Known suspected hypersensitivity study treatment . Prior treatment antiCD20 monoclonal antibody , time , treat monoclonal antibody within 3 month prior start study therapy , exception rituximab instance . Inability comply protocol activity . Pregnant lactate woman female patient childbearing potential ( male patient partner ) willing use adequate contraception 1 year follow dose completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Salvage chemotherapy</keyword>
	<keyword>relapse</keyword>
	<keyword>grade 3B follicular lymphoma</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>DHAP</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>refractory</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Diffuse Large B Cell Lymphoma ( DLBCL )</keyword>
	<keyword>Oncology</keyword>
	<keyword>ICE</keyword>
	<keyword>Transformed follicular lymphoma</keyword>
</DOC>